Solvias Appoints New CEO
Solvias appoints Karen Huebscher as its new CEO.
, a pharmaceutical service provider, has appointed Karen Huebscher to succeed Hansjörg Walther as CEO. Walther will retire and hand over operational management of the company to Huebscher, effective March 1, 2014. In 2000, Huebscher became head of investor relations at Novartis. In 2006, she joined the global executive leadership team of the Vaccines and Diagnostics division, headquartered in the United States.
As a member of the Executive Committee, Huebscher was responsible for business development (in-and out licensing) and M&A. After her return from the US, Huebscher took on responsibility for vaccine marketing in Europe and became site head for the Vaccines & Diagnostics division in Basel. In 2012, she founded Fibula Medical and was also appointed to the Board of Directors of Tecan. Huebscher has been a member of the Board of Directors of Solvias since 2013. Walther will retain his seat on the Board of Directors.
Source:
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
